Biotech Startup Funding Stages: What Investors Expect at Each One

Almost every guide to startup funding stages is written for software. It talks about MVPs, monthly recurring revenue, and product-market fit, and it tells you that Series A is where you prove the business model scales. For a biotech founder, that guide is not just unhelpful. It points you at the wrong evidence, the wrong investors, and the wrong story.

Biotech does not fund on revenue, because there usually is none for the better part of a decade. It does not fund on product-market fit, because the product is still in a freezer. Biotech funds on one thing: scientific de-risking. Each round buys you to the next milestone that lowers the probability your drug fails, and your valuation steps up each time you clear one.

Once you see biotech funding as a milestone ladder, preclinical to IND to Phase 1, 2, and 3, the whole journey makes sense. You know what investors expect at each rung, what your capital is supposed to buy, and when you are actually ready to climb.

This guide: Biotech Startup Funding Stages walks the full ladder, stage by stage, with what investors expect, who writes the checks, how much they write, and what your money is supposed to deliver before you raise again.

Why Biotech Funding Works Differently Than Tech

Before the stages, three structural realities. They explain almost everything that follows, and founders who internalize them stop making the most expensive mistakes.

Milestones, Not Revenue

In software, each round is justified by traction metrics: users, revenue, retention, growth rate. In biotech, each round is justified by a de-risking event: a validated target, IND clearance, a positive Phase 1 readout. Investors are not buying growth. They are buying a reduction in the chance that your science fails.

A typical drug program runs ten to fifteen years from discovery to market, through preclinical work, three phases of clinical trials, and regulatory review, before a single dollar of product revenue exists. Every round you raise is priced against that long, risky horizon, which is why every dollar should be tied to the specific milestone it will deliver. That milestone is the only thing that moves your value.

How Valuation Actually Works

Biotech valuation is probability math, not a revenue multiple. The standard approach, risk-adjusted net present value, takes a drug’s projected future cash flows and weights them by the probability of surviving each clinical phase. Those probabilities are the entire game, and they are sobering.

Even the most optimistic large-scale estimate is humbling. The largest study of its kind, led by Andrew Lo at MIT and built from more than 400,000 trial records, found that a drug entering Phase 1 has roughly a 13.8 percent probability of eventually reaching approval. Industry trackers that measure it differently land lower.

The widely cited BIO, Biomedtracker, and Amplion analysis put the overall likelihood of approval from Phase 1 at 9.6 percent, and identified Phase 2 as the single hardest transition of all, with a success rate around 30.7 percent, well below Phase 1 or Phase 3.

More recent data is harsher still: Citeline’s analysis of the 2014 to 2023 period shows the likelihood of approval falling to about 6.7 percent, with Phase 2 the main graveyard at roughly a 28 percent transition rate.

Here is why that matters for your raise. Because value is probability-weighted, clearing a phase produces a step-change, not a smooth climb. A program that moves from Phase 2 into Phase 3 does not get incrementally more valuable. It re-rates, because the odds of eventual approval just jumped. Your entire fundraising strategy is really a strategy for buying your way up that probability curve, one milestone at a time.

The Funding Gap That Favors De-Risked Companies

Capital in biotech skews late, and it has skewed later since the 2021 peak burst. In 2025, biotech venture funding totaled about $33.8 billion across 1,171 deals, per PitchBook, but the share going to early-stage companies fell to just 32 percent, down from over 40 percent during the 2020 to 2022 boom. The median early-stage deal grew larger even as the count shrank, which tells you investors are writing bigger checks into fewer, more mature companies.

The first quarter of 2026 made the gap explicit. J.P. Morgan tracked 50 seed and Series A deals worth $2.3 billion against 51 Series B and later deals worth $4.5 billion, with investors openly prioritizing companies that have established data packages, de-risked development, and near-term catalysts.

The implication for founders is strategic, not just descriptive: the further up the milestone ladder you climb, the more capital opens up to you. Early rounds are about earning your way to the stage where the larger pools of money live.

Stage 1: Pre-Seed and Non-Dilutive Funding

The earliest money buys you the right to begin. It rarely arrives as a single priced equity round. It is usually a layer cake of non-dilutive grants, accelerator funding, and a small pre-seed equity raise, stacked together to fund the work that validates a scientific hypothesis before any institutional investor will engage.

Who invests and how much. Founders themselves, friends and family, and angels with domain expertise. Accelerators built for this stage, where SOSV’s IndieBio is the archetype: it writes $250,000 in initial funding for roughly 8 percent equity, up to $525,000 total including a milestone-based follow-on, targeting around 10 percent ownership by the seed round, alongside wet-lab space and a structured cohort. And non-dilutive grants, above all the federal SBIR and STTR programs.

Non-dilutive capital deserves special attention here, because it is the cleanest money you will ever raise. The SBIR and STTR programs, often called America’s Seed Fund, distribute billions a year across eleven federal agencies to U.S.-owned small businesses with fewer than 500 employees, funding early R&D without taking a share of your company.

One important update for 2026 planning: the programs’ authorization lapsed on September 30, 2025, froze new awards for roughly six months, and was then reauthorized through fiscal year 2031 when the Small Business Innovation and Economic Security Act was signed on April 13, 2026.

Several agencies raised their award ceilings on restart, and the longest authorization in the programs’ history means founders can finally plan multi-phase grant strategies without a near-term expiration hanging over them. Typical biotech-relevant amounts run from a few hundred thousand dollars at Phase 1 to well over a million at Phase 2, depending on the agency.

Round sizes at this stage are small, typically a few hundred thousand to a couple of million dollars across all sources combined.

What the capital buys. Pre-seed money should carry you to your first real de-risking proof point: early validation of your target or your approach, enough to justify a seed round. Nothing more. The job is to convert a thesis into the first piece of evidence. If you are raising at this stage with no clinical data behind you, the full playbook for doing it credibly is in pre-seed biotech fundraising with no clinical data.

What investors expect at this stage:

There is no data to evaluate yet, so investors are betting on three things and three things only:

• A credible scientific hypothesis grounded in real preliminary evidence, even if that evidence is limited to academic literature or early lab observations. The mechanism has to be compelling and specific, not a vague claim that a pathway “looks promising.”
• A founding team with the domain expertise to plausibly pursue it, including at least one technical co-founder with relevant scientific or clinical credentials. At this stage you are funding founders before the science is de-risked, which only a specific kind of investor does, and they do it on the strength of the people. How those founders are perceived publicly matters more than most scientists expect, which is the case for why biotech CEOs need a personal brand before they raise.
• Early intellectual property thinking, even if no patent has been filed. Investors want to see that you understand what is defensible and have a plan to protect it.
• A narrow, specific use of funds tied to a single proof-of-concept milestone, not a broad multi-year roadmap. Grant reviewers in particular reward a tightly scoped research plan with clear success criteria, because SBIR and similar programs evaluate technical merit and feasibility above all else.

Stage 2: Seed Funding

Seed is where a biotech company raises its first meaningful priced equity round, usually once the pre-seed work has produced enough preliminary data to attract dedicated seed-stage investors rather than relying solely on grants and angels. This is where you generate the data that makes everything downstream possible.

Who invests and how much. Dedicated seed funds, life-science angels, and continued non-dilutive grants. Biotech seed rounds vary widely, commonly running from a couple of million dollars up to the low tens of millions, with a small number of high-profile platform seeds raising far more.

Those headline mega-seeds are the exception, not the benchmark, and founders who anchor their expectations to them set themselves up for a painful raise. Plan for a runway of twelve to eighteen months and a burn rate that matches the experiments you actually need to run.

What the capital buys. The bulk of seed capital, often the large majority, goes to research and development, with the rest covering IP protection, incorporation, and early team building. The goal is to move from a validated idea toward IND-enabling work: target validation, lead optimization, and the preclinical foundation your Series A will be built on.

What investors are doing at this stage. Seed investors are still backing potential, but they want to see the science taking shape rather than just described. They accept high risk in pursuit of outsized returns, knowing most early biotech bets will not pay off, and they price that risk into both valuation and ownership.

The competitive bar has also risen: today’s seed environment in biotech resembles what Series A looked like a few years ago, with sharper selectivity and a higher expectation of real data.

What investors expect at this stage:

• Preliminary in vitro or in vivo validation data that supports the core hypothesis, not just a literature-backed rationale. The conversation has moved from “this should work” to “here is early evidence that it does.”
• A credible IP position, ideally with a provisional patent filed.
• Evidence that the team executed against its pre-seed plan. A track record of hitting your own self-set milestones is one of the strongest signals available at this stage, because it predicts whether you will hit the next set.
• A roadmap that names the specific preclinical milestones the seed round will fund and shows how they position the company for a Series A.
• Early commercial or regulatory awareness, increasingly. Seed investors now look for a team that includes more than scientific credibility alone, even if that awareness is still nascent.

Stage 3: Series A

Series A is the hardest jump in the biotech funding journey, because it is where the bar changes from potential to proof. A modern biotech Series A is no longer raised on a promising story and a strong team. The evidence requirement steps up sharply, and so does the rigor of diligence.

Who invests and how much. Specialist biotech venture funds lead here, and they take board seats to protect the bet. Round sizes vary enormously. Plenty of biotech Series A rounds land in the mid-teens to $50 million range, while platform companies and hot therapeutic areas push well past $100 million.

Recent examples illustrate the spread: in early 2026, investors put $130 million into Slate Medicine and $95 million into Poplar Therapeutics across initial and extension rounds, and the 2026 fundraising tracker recorded a $125 million Series A for Coultreon Biopharma to push its lead autoimmune program from Phase 1 toward Phase 2.

On valuation, the broad-market signal is real money, not a story: the median Series A post-money valuation reached a record $78.7 million in Q4 2025, per Carta, though in biotech specifically that number is anchored in clinical milestones and technology strength rather than revenue. Typical dilution runs 15 to 30 percent.

What the capital buys. Series A funds the move into the clinic: completing IND-enabling studies and beginning early human trials. This is the round that converts a preclinical asset into a clinical-stage company. For the stage-specific playbook on clearing the 2026 bar, valuation, and process, see how to raise a biotech Series A in 2026.

What investors are doing at this stage. The mindset shifts. Seed backers chase very high multiples on long odds. Series A investors aim for more modest returns with a lower chance of failure, which is exactly why they demand more data and take governance roles. They are underwriting execution risk now, not just scientific possibility, and they price accordingly.

What investors expect at this stage:

• IND-ready data, and increasingly the initiation of Phase 1 trials. In practice that means completed preclinical toxicology, IND-enabling studies, a manufacturing plan, and prepared regulatory documentation. This is a materially higher bar than the proof-of-concept that sufficed at seed.
• A clear, credible regulatory pathway, often validated through a pre-IND meeting with the FDA.
• Strong IP protection, ideally with patents filed or granted rather than merely provisional.
• A diversified pipeline, or at least a clearly articulated plan to expand beyond the lead program.
• Operational depth on the team, people who can take a program through IND-enabling work and into the clinic, not only the scientists who generated the original hypothesis.
• Strategic partnerships or early pharma engagement, where they exist, treated as meaningful external validation.

Stage 4: Series B

If Series A funds the leap to the clinic, Series B funds the evidence that you belong there. It is a growth round, and the evaluation criteria shift decisively from preclinical promise to early human data. The question changes from “does the science work” to “is this drug going to make it.”

Who invests and how much. Late-stage venture funds, crossover investors who bridge private and public markets, and strategic or corporate venture arms enter here, often alongside Series A investors who participate again to defend their ownership in what is known as an inside or follow-on round. Rounds grow substantially.

Real 2025 examples include a $141 million Series B for gene-therapy developer AAVantgarde to push two eye-disease programs through the clinic, and the 2026 tracker logged a $125 million Series B for SonoThera to move its lead programs into the clinic. The strongest rounds, backed by compelling clinical data and pharma partnerships, can exceed $150 million. Typical dilution runs 15 to 25 percent.

What the capital buys. Series B typically funds the expansion from a single Phase 1 or Phase 2 trial into a broader clinical program: additional indications, larger trials, and the manufacturing scale-up needed to support later-stage work.

What investors are doing at this stage. The investor base broadens precisely because the risk has come down. With early human data in hand, the company becomes legible to a wider pool of capital that would not have touched it preclinically. These investors weight clinical differentiation and regulatory clarity heavily, and they scrutinize whether the Series A capital actually produced risk reduction.

What investors expect at this stage:

• Phase 1 or Phase 2 clinical data with a clear, well-articulated differentiation story against the existing standard of care, not just a safety signal.
• Evidence the lead program is on a credible timeline toward a pivotal trial or a meaningful clinical readout.
• A pipeline strategy that shows how the capital will be deployed across additional indications or programs, not just the original lead asset.
• Demonstrated capital efficiency from Series A, because investors are explicitly evaluating whether prior capital translated into genuine de-risking.
• Strategic partnerships with pharmaceutical companies or research institutions, weighted heavily as external validation of commercial relevance.

Stage 5: Series C and Beyond

By Series C, a biotech company has typically generated clinical data strong enough to change the conversation. The work is no longer proving the hypothesis. It is scaling a validated program and positioning for a liquidity event.

Who invests and how much. The capital sources widen again, well beyond traditional venture. Private equity firms, hedge funds, sovereign wealth funds, and crossover funds frequently participate at Series C and later, attracted by the prospect of a near-term IPO or acquisition.

Round sizes scale to match the cost of late-stage trials, often landing in the $80 million to $200 million range and sometimes far higher for companies running multiple programs. Series D rounds, where they occur, tend to serve a specific purpose: addressing an unmet milestone, extending international expansion, or strengthening the balance sheet ahead of an exit. Typical dilution narrows to 10 to 20 percent as valuations climb.

What the capital buys. Registration-enabling work, late-stage and pivotal trials, and the operational buildout of a company preparing to be public or acquired. Companies with several assets advancing command higher valuations, because a diversified pipeline spreads the binary risk that any single trial carries.

What investors are doing at this stage. Late-stage investors are underwriting a path to liquidity within a defined window, so they care about execution speed and capital efficiency more than about whether the science works at all, which they now largely assume. Diligence is materially deeper than at any earlier round, and financial history gets examined with precision.

What investors expect at this stage:

• Established, predictable scientific or clinical progress, with high confidence the lead program reaches its next major readout.
• A credible exit narrative, whether IPO, strategic acquisition, or a major licensing deal, because later-stage investors are explicitly underwriting a route to liquidity.
• Strong cash discipline and reliable partnerships or contracts. Late-stage investors in this market have shown a clear preference for financial and operational maturity over story.
• Detailed, precise financial history, since due diligence here goes deeper than at any earlier round.
• A clear rationale for the round size relative to faster-moving sectors, given biotech’s longer development cycles and higher infrastructure costs.

Stage 6: Late-Stage, Pre-IPO, and Crossover Rounds

The final private funding stage before a public listing or acquisition involves a distinct class of investor whose very presence signals where a company sits in the market’s confidence cycle.

Who invests and how much. Crossover investors, funds that hold both private and public biotechs, anchor this stage, often alongside hedge funds and mega-funds. They re-enter the space and lift the valuations of pre-IPO companies as market conditions improve, and they pull back when the IPO window narrows.

Their willingness to take a pre-IPO position is, in effect, a read on the public market itself. Rounds commonly run from $50 million to $200 million and beyond, with dilution typically in the 8 to 15 percent range.

What the capital buys. Pivotal Phase 3 trials, commercial infrastructure built ahead of an anticipated approval, or simply extended runway through a volatile IPO window while the company stays ready to go public when conditions turn favorable.

What investors are doing at this stage. Crossover funds bridge the private and public evaluation criteria, so they price the round partly against how comparable public biotechs are currently valued. Companies with strong clinical data continue to secure this capital, while weaker companies struggle without credible proof-of-concept milestones already behind them.

What investors expect at this stage:

• Strong, de-risked clinical data, typically from a pivotal trial that is complete or far enough along that the outcome is reasonably predictable.
• A credible regulatory submission timeline, with FDA or EMA interactions already well underway.
• Commercial readiness, including early thinking on pricing, market access, and manufacturing scale-up.
• A public-market comparable set the company can be benchmarked against, since crossover funds price partly off public peers.

Stage 7: IPO and Exit

The public markets, or an acquisition, represent the terminal stage of the venture-funded biotech journey. The timing of this transition is tied to clinical milestones more tightly than in almost any other startup category. IPO readiness is not primarily a financial threshold. It is a clinical and regulatory threshold first, with the financing decision following from where the science actually stands.

The two paths. Most biotech IPOs happen after successful Phase 2 data or in anticipation of an FDA filing, at a point when the company needs a large capital injection for manufacturing scale-up or commercial launch. The traditional underwritten IPO remains the most common public route, though a SPAC merger offers a faster, less common alternative.

But not every biotech goes public, and acquisition is an equally valid and, for many companies, the more likely outcome. M&A remains the dominant exit, and many biotechs are built specifically to be acquired rather than to list.

The first quarter of 2026 underlined how active this channel is: large-cap buyers struck 32 takeovers worth $40.9 billion in upfront value, including Merck’s $6.7 billion deal for Terns and Lilly’s $6.3 billion offer for Centessa. Structuring for an acquisition from early on is a legitimate strategy, not a fallback.

What investors and acquirers expect at this stage:

• For an IPO: successful Phase 2 data with a clear path to Phase 3, or a pending FDA filing with a realistic approval timeline, plus a management team able to operate as a public company, with financial-reporting discipline and investor-relations capability.
• For an acquisition: a clear fit with the acquirer’s existing pipeline or therapeutic focus, a strong and broad IP estate, and a well-understood estimate of the remaining capital and timeline to market.
• In both cases: clinical validation specific enough that the remaining risk is well understood and can be priced with confidence, rather than a broad assertion that the science is promising.

The Full Biotech Funding Stage Comparison Table

Not every company follows a rigid path through these stages. Some skip rounds, combine them, or raise hybrid structures depending on traction, market timing, or a specific strategic opening. What matters is aligning the round with the company’s actual scientific and regulatory maturity, not forcing a label onto the raise because it is the conventional next step.

The figures below are indicative ranges, not guarantees, and vary widely by therapeutic area and modality.

Stage	Typical Raise Size	Milestone Required	Primary Investors	Use of Funds	Typical Dilution
Pre-Seed / Non-Dilutive	$250K to ~$2M	Founding team, scientific thesis, IP, first proof-of-concept	SBIR/STTR grants, accelerators (IndieBio), angels, university tech transfer	Proof-of-concept, IP, team building	~8 to 20% (where equity)
Seed	~$2M to $15M	Target validation, early in vitro / in vivo data	Seed-stage VCs, life-science angels, continued grants	Lead optimization, IND-enabling groundwork	~15 to 25%
Series A	Mid-teens to $50M+ (platform rounds $100M+)	IND-ready data or Phase 1 initiation	Specialist biotech VCs	IND-enabling studies, Phase 1 trial	~15 to 30%
Series B	~$50M to $150M+	Phase 1/2 data with clear differentiation	Late-stage and crossover VCs, corporate venture, inside investors	Phase 2 expansion, pipeline broadening	~15 to 25%
Series C and beyond	~$80M to $200M+	Strong Phase 2 or early Phase 3 data	VCs, private equity, hedge funds, sovereign wealth funds	Late-stage trials, scale, international expansion	~10 to 20%
Late-Stage / Pre-IPO / Crossover	~$50M to $200M+	De-risked pivotal data, IPO readiness	Crossover funds, hedge funds, mega-funds	Pivotal Phase 3, commercial buildout, runway	~8 to 15%
IPO / Exit	Varies, often $100M+	Phase 2 success or pending FDA filing (IPO); strategic fit (M&A)	Public-market investors, crossover funds; strategic acquirers	Manufacturing scale-up, commercial launch	Varies

What Investors Actually Evaluate at Each Stage

The underlying evaluation framework does not change much from stage to stage. What changes is the weighting. Across the entire journey, biotech investors are assessing the same five dimensions: the scientific differentiation and novelty of the mechanism, the quality and experience of the team, the clarity of the regulatory pathway and its de-risking milestones, the size of the addressable market and the depth of unmet need, and the competitive landscape including freedom to operate.

Which dimension dominates shifts as the company matures. At pre-seed and seed, team quality and the scientific rationale carry the most weight, because there is little else to assess. Part of assessing the team now happens before a single meeting, which is why biotech investors Google you before saying yes.

By Series A, validated preclinical data and a credible IND-enabling plan move to the center, shifting the conversation from potential to demonstrated execution. By Series B and beyond, clinical data with clear differentiation becomes essential, and market size and competitive dynamics take on much greater weight as a real commercial decision approaches.

Underneath all of it, investors at every later stage are asking the same three linked questions: what specific inflection point will this capital fund, how much clinical or regulatory risk does crossing that inflection remove, and what does removing that risk do to the valuation at the next round or at exit.

Founders who can answer those three questions with precision, milestone by milestone, negotiate from strength at any point in the lifecycle.

Why the 2026 Bar Is Higher Than 2021 at Every Stage

Founders who benchmark their readiness against 2021 will consistently underestimate what today’s investors expect, because 2021 was an anomaly that is not coming back.

Biotech fundraising in 2020 and 2021 was historically loose. Many seed rounds closed on preclinical proof-of-concept alone, and some Series A rounds closed without the IND-enabling data that is now table stakes.

When the broader venture market corrected in 2022 and 2023, that permissiveness reversed hard, producing a well-documented Series A crunch in which a large share of companies that raised seed in the boom never raised a Series A at all.

The market has since recovered, but on different terms. Capital is flowing again at meaningful volume, yet it is concentrating in fewer, more mature companies: the early-stage share of biotech VC fell to roughly 32 percent in 2025, down from over 40 percent in the 2020 to 2022 period, a meaningful reduction in new company formations and first financings.

The data bar required to access capital at every stage, from seed through Series C, has risen permanently rather than temporarily. The companies clearing that bar are raising at strong valuations. The ones benchmarking against pre-2022 case studies are pitching into a market that no longer exists.

Principles That Apply at Every Stage

Four ideas run the length of the ladder. Internalize them and every individual raise gets easier.

Tie Every Dollar to a Milestone

Investors fund milestones, not open-ended R&D. The market has formalized this preference: even large-cap licensing deals now push the bulk of their value into milestone-based back-end payments rather than upfront cash, and venture rounds are increasingly tranched, with capital released against specific achievements like candidate nomination or IND-enabling studies.

Whether or not your round is formally tranched, present it that way. Here is the milestone, here is what it costs, here is the value it unlocks. That framing is what investors are trained to fund.

Sequence Non-Dilutive Capital Early

Grants and other non-dilutive funding do not cost you equity, so use them early, to reach the milestones that raise your valuation before you ever sell ownership. SBIR and STTR awards, NIH grants, and disease-specific foundation funding can cover exactly the validation work that qualifies you for your next equity round.

Sequencing non-dilutive money ahead of your first priced rounds is one of the cleanest ways to minimize dilution across the entire journey.

Know Whether You Are a Platform or an Asset

Decide which story you are telling, because the two are valued on different terms. Platform companies generate many programs from a single engine and have become investor favorites, valued on the breadth of what the platform can produce.

Asset companies are built around a single lead program and are valued on the risk-adjusted value of that asset. Both raise successfully. Blurring the line between them confuses investors and weakens the pitch.

Raise Around Value-Inflection Points

The strongest fundraising timing is just before a major readout, while the risk is still priced into your valuation, then deploying that capital to deliver the de-risking data that resets your valuation upward for the next round.

Aim for eighteen to twenty-four months of runway per round so you always reach a value-inflection milestone before you have to raise again. The goal is never to raise from a position of weakness, with a depleted balance sheet and no near-term catalyst.

Common Mistakes Founders Make When Navigating Funding Stages

Treating each round as a bigger version of the last. The most common error is assuming a Series A pitch is just a seed pitch with a larger ask and a longer deck. Each stage is a qualitative shift in what investors evaluate, not a quantitative one. Founders who do not adjust the narrative waste months pitching the wrong question to the wrong investors.

Raising the wrong amount for the milestone. Founders frequently raise to a target valuation or a number their peers hit, rather than working backward from the specific milestone the capital must fund. The result is either running out of runway before the milestone is reached, or taking on more dilution than the risk being removed actually justifies.

Skipping non-dilutive funding entirely. Moving straight to angel or seed equity without first pursuing grants or accelerator funding dilutes ownership earlier and more than necessary, when non-dilutive capital was available to fund the same early validation.

Failing to model cumulative dilution. Each round dilutes ownership, and dilution compounds across rounds in ways that are easy to underestimate when looking at any single raise in isolation. Founders who do not model the full path often discover they own a much smaller share of a large outcome than they expected.

Pursuing a stage label instead of the milestone. Calling a round a “Series A” because of the dollar amount, when the company’s milestone profile looks more like a late seed, creates friction in diligence. Investors evaluate the substance of the milestone, not the label, and a mismatch between the two is a tell.

Locate Yourself on the Ladder

Before you plan a raise, place yourself honestly. The most expensive mistake is raising for the wrong rung.

• Idea and team, no data: you are at pre-seed. Focus on team, thesis, IP, and the path to your first proof point.
• Validating the science: you are at seed. Drive toward IND-enabling work.
• IND-ready, heading to the clinic: you are at Series A. The bar is real data now, not a story.
• Clinical data in hand: you are at Series B and beyond, where the investor base broadens and the rounds grow.

At every rung the logic is identical. Identify the next de-risking milestone, raise enough to reach it with margin, tie every dollar to it, and target the investors who fund companies at exactly your stage.

A Practical 12-Month Roadmap for Your Next Funding Stage

Q1: Assess Your Stage Honestly (Months 1 to 3)

The first quarter is an evidence-based audit of where you actually sit relative to your next intended round.

• Benchmark your current data package against the milestone requirements for your next stage, using the comparison table above as a starting reference for your therapeutic area and modality.
• Identify the single largest gap between your current readiness and what investors at your target stage require. It is usually a specific piece of preclinical data, a regulatory interaction that has not happened, or a team capability you have not built.
• Audit your cap table and prior round terms to understand how much dilution has occurred and how much capacity remains before the next round meaningfully erodes founder ownership.
• Review your non-dilutive options if you have not exhausted them. SBIR Phase 1 and Phase 2 applications, NIH grants, and foundation funding can extend runway and fund the exact milestone work you need.
• Set a milestone-driven timeline for closing the gap, not an arbitrary calendar deadline.

Q2: Close the Gap Through Focused Execution (Months 4 to 6)

The second quarter is about the scientific, regulatory, or commercial work that actually changes your stage readiness, not premature fundraising.

• Execute the specific experiments or studies identified in Q1 as the critical gap.
• Pursue the relevant regulatory interaction, such as a pre-IND meeting with the FDA, if it is required for your next stage and has not yet happened.
• Build the financial model and data room appropriate to your next stage, since Series A and beyond demand materially more rigorous documentation than seed diligence. The complete slide-by-slide guide to the biotech and life science investor pitch deck covers what belongs in the narrative and the supporting materials.
• Begin tracking the metrics investors at your next stage will scrutinize, whether preclinical efficacy, Phase 1 safety signals, or early commercial traction.

Q3: Build Your Stage-Matched Investor Pipeline (Months 7 to 9)

The third quarter is about identifying and warming up investors whose stage focus matches where you will be when you formally raise. The window before a raise is also when you should be building biotech founder visibility before a fundraise, so the investors you approach already recognize your name.

• Build a target investor list matched to your next stage, since the funds active at seed differ meaningfully from those active at Series B or late-stage. The methodology is in how to find and qualify investors for a biotech or healthcare startup.
• Begin warm-introduction mapping and value-first outreach to your highest-priority targets six to nine months before your planned close, using the full framework in how to build an investor pipeline for biotech and medtech founders.
• Attend the conferences where your stage’s investors actually are. An early-stage venue draws a different crowd than a crossover-focused one.
• Send a quarterly progress update to advisors, angels, and prior investors, documenting the milestone progress that positions you for the next round.

Q4: Execute the Raise (Months 10 to 12)

The fourth quarter converts nine months of preparation into a formal, well-targeted process.

• Launch outreach to your full stage-matched list in parallel, not sequentially, to create the competitive dynamics that improve terms. If past rounds stalled at this step, why biotech investor outreach fails and how to fix it covers the most common breakdowns.
• Frame your narrative around the milestone your prior round funded and the milestone this round will fund, making the de-risking logic explicit.
• Negotiate valuation from that milestone narrative, anchoring your ask to the specific risk your capital removes.
• Manage your pipeline actively through close, tracking every investor’s stage and next action until the round is fully subscribed.

Match the Round to the Milestone, Not the Other Way Around

Biotech funding is not the software funding story with longer timelines. It is a fundamentally different game, played on a milestone ladder where each round buys a reduction in scientific risk and each cleared milestone steps up your value.

Pre-seed and seed fund the team and the science, backed by angels, accelerators, and grants. Series A funds the leap to the clinic, and the bar is now real data, not a story. Series B and C fund clinical proof and scale, with broader and larger investors as the risk comes down. And the exit, usually an acquisition rather than an IPO, is what the whole ladder is built toward.

Founders who internalize this stop asking “what stage should I raise” and start asking “what specific milestone does my company need to hit next, and which investors fund exactly that milestone.” That reframing changes everything: how much to raise, whom to approach, and how the pitch should be structured and positioned, which is the core of capital raise marketing for biotech, medtech, and diagnostics.

Map your journey as a sequence of de-risking milestones, raise around each one, match your pitch to what investors actually expect at your rung, and the stage label takes care of itself.

---

Book a Strategy Call to map your funding stages and milestone plan, or Explore My Services to see how investor targeting, positioning, and outreach come together at every stage of the raise.

---

Frequently Asked Questions

---